How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?Zacks Investment Research • Wednesday
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight lossBusiness Insider • Wednesday
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialPRNewsWire • Wednesday
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top PickSeeking Alpha • Tuesday
Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unitReuters • Tuesday
Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global MarketsPRNewsWire • Tuesday
4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialZacks Investment Research • Tuesday
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsZacks Investment Research • Tuesday
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?Zacks Investment Research • Monday
Lilly (LLY) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • Monday
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPRNewsWire • 10/25/26
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PRNewsWire • 10/24/26